GlassScriptPhysician profile
William R Sunter
NPI 1083699151
$76,204.85
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $23K · 2021: $24K · 2022: $4,213.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $63,803.06 | 2019-2022 | |
| Abbvie INC. | $10,028.40 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $472.13 | 2019-2021 | |
| Emd Serono, INC. | $260.60 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $204.57 | 2019-2021 | |
| Lundbeck LLC | $145.64 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $130.37 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $109.28 | 2019-2021 | |
| Greenwich Biosciences, INC. | $108.14 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $94.44 | 2019-2021 | |
| Lilly USA, LLC | $90.92 | 2019-2021 | |
| Amgen INC. | $61.65 | 2019-2020 | |
| Mdd US Operations, LLC | $54.29 | 2019-2020 | |
| Biogen, INC. | $47.33 | 2019 | |
| Upsher-Smith Laboratories LLC | $44.50 | 2020 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $39.93 | 2019 | |
| Genentech USA, INC. | $36.26 | 2020-2021 | |
| Ipsen Biopharmaceuticals, INC | $36.15 | 2020-2021 | |
| Livanova USA, INC. | $34.98 | 2019-2020 | |
| Eisai INC. | $33.58 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.16 | 2021 | |
| Alexion Pharmaceuticals, INC. | $29.24 | 2019 | |
| Genzyme Corporation | $29.19 | 2019-2021 | |
| Adamas Pharmaceuticals, INC. | $28.63 | 2019-2020 | |
| Csl Behring | $27.66 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $23.08 | 2021 | |
| Janssen Pharmaceuticals, INC | $22.18 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $20.18 | 2021 | |
| Scilex Pharmaceuticals INC. | $19.56 | 2021 | |
| Assertio Therapeutics, INC. | $19.35 | 2019 | |
| Celgene Corporation | $17.87 | 2021 | |
| Merz North America, INC. | $16.22 | 2019 | |
| Mallinckrodt Enterprises LLC | $15.53 | 2019 | |
| Merz Pharmaceuticals, LLC | $14.69 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.00 | 2021 | |
| Portola Pharmaceuticals, LLC | $13.62 | 2019 | |
| Boston Scientific Corporation | $13.26 | 2021 | |
| Grifols USA, LLC | $13.21 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Sunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.